Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
05 Outubro 2023 - 9:30AM
Business Wire
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression, and other central nervous system
(CNS) disorders, today announced that the Company will present and
host one-on-one meetings at the Jefferies Biotech CNS/Neuro Summit
taking place October 11 – 12, 2023 in New York City, New York.
Jefferies Inaugural Biotech CNS/Neuro Summit Details
Fireside Chat Date and Time: Thursday, October 12, 2023 at 12:00
p.m. Pacific Time Location: Jefferies Conference Center in New York
City, New York
A webcast will be accessible through the Events page in the
Investors section of the Company’s website at www.Vistagen.com.
Investors interested in arranging a one-on-one meeting during the
conference should contact their Jefferies representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression, and
other CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those currently available for the treatment
of anxiety, depression, and multiple CNS disorders. Vistagen's
pipeline includes six clinical-stage product candidates, including
fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284, each an
investigational agent belonging to a new class of drugs known as
pherines, as well as AV-101, which is an oral prodrug of an
antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines
are neuroactive nasal sprays designed with an innovative proposed
mechanism of action that activates chemosensory neurons in the
nasal cavity and can beneficially impact key neural circuits in the
brain without systemic absorption or direct activity on neurons in
the brain. Vistagen is passionate about transforming mental health
care and redefining what is possible in the treatment of anxiety,
depression, and several other CNS disorders. Connect at
www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005492188/en/
Investors: Mark McPartland Senior Vice President, Investor
Relations (650) 577-3606 markmcp@vistagen.com
Media: Nate Hitchings SKDK nhitchings@skdknick.com
VistaGen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024